Bristol-Myers Squibb CompanyBMY
▲ PositiveDemandrelevance
Growth portfolio sales rose 13% in H1, lifting revenue share to 56%.
Impact on stocks 3
Biotech & Genomic Medicine
Bristol Myers Growth Portfolio Sales Rise 13% in First Half
Earnings
Bristol Myers Squibb's growth portfolio sales rose 13% in the first half of 2026, lifting its share of total revenues to 56% from 51.8% a year earlier. The portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy. Opdivo Qvantig is now generating annualized revenues of more than $1 billion. Legacy products including Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane still account for 44% of revenues and face erosion from loss of exclusivity. Bristol Myers shares have gained 17.9% year to date, and the Zacks Consensus Estimate for 2026 EPS has risen to $6.81 from $6.32 over the past 60 days.
Bristol-Myers Squibb CompanyGrowth portfolio sales rose 13% in H1, lifting revenue share to 56%.
Merck & Company Inc
Pfizer Inc